Paper28039262
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
Dong ZY and 18 others. Clin Cancer Res, 2017. Cited by 852 papers, by iCite.
Cite this record
ConductScience Library. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Papers, record 28039262. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28039262
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma | Major topic |
| B7-H1 Antigen | Major topic |
| Immunotherapy | Major topic |
| Lung Neoplasms | Major topic |
| Programmed Cell Death 1 Receptor | Major topic |
| Proto-Oncogene Proteins p21(ras) | Major topic |
| Tumor Suppressor Protein p53 | Major topic |
| Adenocarcinoma of Lung | |
| Biomarkers, Tumor | |
| Female | |
| Humans | |
| Male | |
| Mutation | |
| Prognosis | |
| Proteomics |
Source PubMed
Cited by683
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 852 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42938349 | Clinical Utility of Broad-Panel Profiling in Non-Small Cell Lung Cancer: Pairwise Co-Mutational Gene Patterns and PD-L1 Associations Define Stage-Specific Prognosis. | Genes (Basel) | 2026 | https://conductscience.org/library/papers/42938349 | PubMed |
| 42936912 | Uncovering KRAS-mutant allele-specific biology and vulnerabilities in non-small cell lung cancer. | Biochem J | 2026 | https://conductscience.org/library/papers/42936912 | PubMed |
| 42934724 | The evolving role of TP53 mutation in hepatocellular carcinoma (HCC). | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/42934724 | PubMed |
| 42870812 | Impact of different TP53 mutation subtypes on response and outcome in advanced lung adenocarcinoma receiving first-line immunotherapy or chemo-immunotherapy. | Transl Lung Cancer Res | 2026 | https://conductscience.org/library/papers/42870812 | PubMed |
| 42852084 | The lung-gut-brain axis in non-small-cell lung cancer: a narrative review with a systematic search of three signaling pathways. | Front Immunol | 2026 | https://conductscience.org/library/papers/42852084 | PubMed |
| 42762412 | SERPINE1 promotes CRC cell invasion and metastasis through resistance to anoikis. | Mol Cell Biochem | 2026 | https://conductscience.org/library/papers/42762412 | PubMed |
| 42761382 | Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC. | Genes Dis | 2027 | https://conductscience.org/library/papers/42761382 | PubMed |
| 42738389 | Real-World Treatment Patterns and Clinical Outcomes After First-Line Therapy in Patients with KRAS G12C-Mutant Advanced Non-Small-Cell Lung Cancer in the United States. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42738389 | PubMed |
| 42733756 | Prevalence of High Programmed Death-Ligand 1 Expression in Pulmonary Sarcomatoid Carcinoma: A Systematic Review and Meta-Analysis. | JTO Clin Res Rep | 2026 | https://conductscience.org/library/papers/42733756 | PubMed |
| 42726875 | Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. | Sci Adv | 2026 | https://conductscience.org/library/papers/42726875 | PubMed |
| 42724286 | A narrative review of immune checkpoint inhibitor-related cardiotoxicity in lung cancer: mechanisms, risk stratification, and clinical management. | J Thorac Dis | 2026 | https://conductscience.org/library/papers/42724286 | PubMed |
| 42629524 | Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy. | Apoptosis | 2026 | https://conductscience.org/library/papers/42629524 | PubMed |
| 42500683 | KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42500683 | PubMed |
| 42452696 | KRAS Mutation Subtypes, Co-Mutations, PD-L1 Expression, and Survival Outcomes in Non-Small Cell Lung Cancer. | J Clin Med | 2026 | https://conductscience.org/library/papers/42452696 | PubMed |
| 42431967 | Genetic drivers of etiologic heterogeneity in thyroid cancer. | Nat Commun | 2026 | https://conductscience.org/library/papers/42431967 | PubMed |
| 42414255 | Aging and cancer: current understandings and future perspectives. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42414255 | PubMed |
| 42409767 | mTORC1 suppression by Trp53 mutation drives resistance to immune checkpoint blockade. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42409767 | PubMed |
| 42327096 | mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment. | bioRxiv | 2026 | https://conductscience.org/library/papers/42327096 | PubMed |
| 42304441 | Immunotherapy resistance in colorectal cancer: therapeutic strategies and biomarker-guided approaches. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/42304441 | PubMed |
| 42297823 | Tumor suppressor genotype influences the extent and mode of immunosurveillance in lung cancer. | Nat Commun | 2026 | https://conductscience.org/library/papers/42297823 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28039262
GET https://conductscience.org/api/papers/v1/28039262/cited_by?page=2